ARUP's Laboratory Test Directory
| 0080206: Prostate Specific Antigen, Free Percentage (Includes Free PSA & Total PSA) |
| Test Mnemonic: PSA FP | |
|
Methodology: Electrochemiluminescent Immunoassay
Performed: Sun-Sat Reported: Within 24 hours |
| Specimen Required: | |
|
Collect: One 4 mL SST or PST. Also acceptable: green (sodium or lithium heparin), lavender (EDTA), or pink (K2EDTA).
Transport: 1 mL serum or plasma, frozen. (Min: 0.5 mL) Submit specimen in an ARUP Standard Transport Tube. Remarks: Allow specimen to clot completely at room temperature before centrifuging. Separate serum or plasma from cells ASAP. Unacceptable Conditions: Grossly hemolyzed specimens. Stability: After separation from cells: Ambient: 8 hours; Refrigerated: 2 days; Frozen: 3 months |
|
| Reference Interval: |
|
By report Results include: PSA-Free, PSA, PSA-Percent Free |
| Interpretive Data: | |||||||||||||||||||||||||||||
|
The Roche Modular E170 PSA electrochemiluminescent immunoassay is used. Results obtained with different assay methods or kits cannot be used interchangeably. The Roche Modular E170 PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche Modular E170 PSA method is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy men or men with non-prostatic carcinoma. ARUP uses the Roche Modular E170 Free PSA method in conjunction with the Roche Modular E170 PSA method to determine the free PSA percentage. The free PSA percentage is an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 and older with a total PSA between 3 and 10 ng/mL and negative digital rectal examination findings. Prostatic biopsy is required for the diagnosis of cancer. (Refer to: JAMA 1998; 279: 1542-1547)
|
|||||||||||||||||||||||||||||
| Note: | |
| The free percentage is calculated using the total and free PSA results. |
| CPT Code(s): | |
| 84153 PSA, total; 84154 PSA, free |